< Back to latest news & events

News

The Vedanta Opposition: A healthy sign of a maturing industry

September 2019

HGF Partners Craig Thomson and Rachel Fetches comment and analyse the “Vedanta Opposition” in Microbiome Times.

As we move towards marketing approval for microbiome therapeutics, the “value” of the microbiome industry is increasing exponentially. This will inevitably result in disputes between the leading competitors seeking to protect their key intellectual property (IP) rights, including patent monopoly rights.

The most significant challenge to patent rights in the therapeutic microbiome field to-date is the recently issued decision in the “Vedanta Opposition”. The patent (European Patent No. 2575835) was granted to the University of Tokyo (UoT) in October 2016.

Within the 9-months after grant, the European Patent Office (EPO) received six Oppositions from Seres Therapeutics, Nestec and four anonymous parties. The Opposition hearing lasted three days and almost 130 documents were considered. Ultimately, the patent was maintained by the EPO’s Opposition Division (OD) but in an amended form, with a narrowed claim scope; this decision has been appealed and it will likely be at least 2 years until the Appeal is heard.

Some elements of the claims raise difficulties for prospective patentees in the microbiome field as it enforces second use claims of this type in the national courts. Where does the OD’s decision leave Vedanta commercially?

Read the full article here.

Latest updates

HGF Ranked #1 in the UK for Trade Mark Portfolios in the 2025 Trade Mark Filing Trends Report by Clarivate.

HGF has achieved the #1 ranking for the UK for trade mark portfolios in the newly released 2025 Trade mark Filing Trends report by Clarivate, recognising the firm as a …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

Celebrating exam success at HGF!

We are once again delighted to share that our colleagues have achieved success in their recent exams! Their dedication, perseverance, and commitment to professional development have paid off, and we …

Read article

Is the Supreme Court denial in Thatcher’s case a fatal blow against lookalikes?

The dispute between Thatcher’s Cider Company and Aldi Stores Limited has been long running and has sparked legal controversy along the way. On 4th June 2025 the Supreme denied Aldi …

Read article

HGF ranked among Europe’s top patent firms in IP STARS Patent Rankings 2025

HGF has once again made a bold mark in the latest Managing IP Stars 2025 firm rankings, with top-tier recognition across multiple jurisdictions for our patent expertise. This year’s results …

Read article

The Enlarged Board of Appeal has today issued its decision in seminal case G1/24

G1/24, described as one of the most important cases in decades, relates to how claims of patents are to be interpreted by the Boards of Appeal and, by extension, all …

Read article

UPC’s Hamburg Local Division provides guidance on the extent to which a patent may be used as its own “lexicon”

Agfa NV v Gucci & Anors. [UPC_CFI_278/2023] – Hamburg Local Division of the UPC (Klepsch, Schilling, Sarlin) – 30 April 2025 While we await a decision on G1/24 from the …

Read article